Xpert MTB/XDR assay: Xpert MTB/XDR sets new standards by detecting mutations associated with resistance towards INH (inhA promoter, katG, fabG1, oxyR-aphC intergenic region), FQs (gyrA and gyrB), second-line injectable drugs (amikacin, kanamycin, capreomycin) (rrs and eis promoter) and ethionamide (ETH) (inhA promoter) in a single assay, while, Xpert MTB/RIF and Xpert MTB/RIF Ultra only diagnose TB and detect resistance to RIF without providing information regarding resistance to other anti-TB drugs [86]. This evidence concerns the gene INHA and tuberculosis.